Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | MYC | P01106 | 1/20 | 0.32 |
| ▸ | WDR5 | P61964 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.31 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.31 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.31 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.31 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.31 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4219879 | 0.79 | HDAC1 (0.50) | NOS1HDAC1HDAC6ALDH1A1HPGD | |
| SCHEMBL23539953 | 0.76 | HCAR2 (0.52) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL25365142 | 0.70 | HDAC6 (0.45) | HDAC1HDAC6HPGD | |
| SCHEMBL1636287 | 0.68 | — | — | |
| SCHEMBL1631557 | 0.68 | — | — | |
| SCHEMBL29035247 | 0.68 | HDAC6 (0.33) | HDAC6 | |
| SCHEMBL4519703 | 0.67 | — | — | |
| SCHEMBL21469422 | 0.67 | — | — | |
| SCHEMBL5875612 | 0.67 | — | — | |
| Water SCHEMBL28159942 | 0.67 | HCAR2 (0.55) | NOS1ALDH1A1HPGDALOX15MYC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338599-B2 | Compounds having a potentiating effect on the activity of ethionamide and uses thereof | INSTITUT PASTEUR DE LILLE (FR) | 2012-12-25 | — | — | US | disclosed |
| US-20110136823-A1 | COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF | INSTITUT PASTEUR DE LILLE (FR) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136823-A1 | COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF | EPX, PGLS, ENPEP | NOS1 689/4885HDAC1 139/4885HDAC6 1471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.